GlassScriptPhysician profile
Victor Altadonna
NPI 1558393611
$3,422.59
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $377 · 2021: $1,883 · 2022: $265 · 2023: $43.45 · 2024: $26.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $69.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $69.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $638.39 | 2021 | |
| Astellas Pharma US INC | $515.85 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $306.17 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $180.57 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $174.07 | 2019-2020 | |
| Janssen Biotech, INC. | $155.37 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.61 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $136.90 | 2021-2022 | |
| Travere Therapeutics, INC. | $114.79 | 2019-2022 | |
| Coloplast Corp | $105.92 | 2020-2023 | Speedicath |
| Abbvie INC. | $93.15 | 2019-2024 | Botox |
| Sun Pharmaceutical Industries INC. | $92.12 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $80.08 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $74.40 | 2021-2022 | |
| Axonics, INC. | $70.40 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $69.50 | 2019-2022 | |
| Foundation Medicine, INC. | $67.04 | 2019-2022 | |
| Urogen Pharma, INC. | $47.57 | 2021-2022 | |
| Urovant Sciences INC | $46.65 | 2021-2022 | |
| Antares Pharma, INC. | $42.63 | 2019-2021 | |
| 180 Medical, INC. | $35.08 | 2019 | |
| Blue Earth Diagnostics | $28.15 | 2021 | |
| Verity Pharmaceuticals INC. | $24.74 | 2021-2022 | |
| Myovant Sciences INC. | $24.74 | 2021 | |
| Allergan, INC. | $23.00 | 2021 | |
| Boston Scientific Corporation | $21.54 | 2022 | |
| Baxter Healthcare | $20.04 | 2021 | |
| Rochester Medical Corporation | $19.68 | 2019 | |
| Emd Serono, INC. | $17.44 | 2019 | |
| Therapeuticsmd, INC. | $16.67 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.44 | 2020 | |
| Olympus America INC. | $13.09 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.80 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$408.78 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Altadonna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.